A Study to Evaluate the Safety of Trabectedin Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
Enrolling By Invitation
10-99 years
All
Phase
1
45 participants needed
1 Location
Brief description of study
This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Ewing Sarcoma
-
Age: Between 10 Years - 99 Years
-
Gender: All
Male or Female, Age 10-99, Diagnosis of relapsed and refractory Ewing sarcoma with EWS-FLI1 fusion type
Updated on
01 Aug 2024.
Study ID: 850614
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
